These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 32532974)
1. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia. Zhao XY; Wilmen A; Wang D; Wang X; Bauzon M; Kim JY; Linden L; Li L; Egner U; Marquardt T; Moosmayer D; Tebbe J; Glück JM; Ellinger P; McLean K; Yuan S; Yegneswaran S; Jiang X; Evans V; Gu JM; Schneider D; Zhu Y; Xu Y; Mallari C; Hesslein A; Wang Y; Schmidt N; Gutberlet K; Ruehl-Fehlert C; Freyberger A; Hermiston T; Patel C; Sim D; Mosnier LO; Laux V Nat Commun; 2020 Jun; 11(1):2992. PubMed ID: 32532974 [TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice. Magisetty J; Kondreddy V; Keshava S; Das K; Esmon CT; Pendurthi UR; Rao LVM Blood; 2022 May; 139(18):2830-2841. PubMed ID: 35143636 [TBL] [Abstract][Full Text] [Related]
3. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. Mosnier LO; Yang XV; Griffin JH J Biol Chem; 2007 Nov; 282(45):33022-33. PubMed ID: 17872949 [TBL] [Abstract][Full Text] [Related]
4. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Müller J; Isermann B; Dücker C; Salehi M; Meyer M; Friedrich M; Madhusudhan T; Oldenburg J; Mayer G; Pötzsch B Chem Biol; 2009 Apr; 16(4):442-51. PubMed ID: 19389630 [TBL] [Abstract][Full Text] [Related]
5. C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities. Yamashita A; Zhang Y; Sanner MF; Griffin JH; Mosnier LO J Thromb Haemost; 2020 May; 18(5):1027-1038. PubMed ID: 32017367 [TBL] [Abstract][Full Text] [Related]
6. Targeting activated protein C to treat hemophilia. Polderdijk SGI; Baglin TP; Huntington JA Curr Opin Hematol; 2017 Sep; 24(5):446-452. PubMed ID: 28632502 [TBL] [Abstract][Full Text] [Related]
7. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C. von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130 [TBL] [Abstract][Full Text] [Related]
8. Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab. Brophy DF; Martin EJ; Mohammed BM; Barrett JC; Kuhn JG; Nolte ME; Wiinberg B; Holmberg HL; Lund J; Salbo R; Waters EK Haemophilia; 2017 Nov; 23(6):941-947. PubMed ID: 28750471 [TBL] [Abstract][Full Text] [Related]
9. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. Kerschen EJ; Fernandez JA; Cooley BC; Yang XV; Sood R; Mosnier LO; Castellino FJ; Mackman N; Griffin JH; Weiler H J Exp Med; 2007 Oct; 204(10):2439-48. PubMed ID: 17893198 [TBL] [Abstract][Full Text] [Related]
10. Activated protein C. Griffin JH; Fernández JA; Gale AJ; Mosnier LO J Thromb Haemost; 2007 Jul; 5 Suppl 1():73-80. PubMed ID: 17635713 [TBL] [Abstract][Full Text] [Related]
11. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Mosnier LO; Zampolli A; Kerschen EJ; Schuepbach RA; Banerjee Y; Fernández JA; Yang XV; Riewald M; Weiler H; Ruggeri ZM; Griffin JH Blood; 2009 Jun; 113(23):5970-8. PubMed ID: 19244160 [TBL] [Abstract][Full Text] [Related]
12. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Elisen MG; von dem Borne PA; Bouma BN; Meijers JC Blood; 1998 Mar; 91(5):1542-7. PubMed ID: 9473218 [TBL] [Abstract][Full Text] [Related]
13. Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha(1)-antitrypsin. Glasscock LN; Gerlitz B; Cooper ST; Grinnell BW; Church FC Biochim Biophys Acta; 2003 Jun; 1649(1):106-17. PubMed ID: 12818196 [TBL] [Abstract][Full Text] [Related]
14. Design and characterization of an APC-specific serpin for the treatment of hemophilia. Polderdijk SG; Adams TE; Ivanciu L; Camire RM; Baglin TP; Huntington JA Blood; 2017 Jan; 129(1):105-113. PubMed ID: 27789479 [TBL] [Abstract][Full Text] [Related]
15. Activated protein C in neuroprotection and malaria. Mosnier LO Curr Opin Hematol; 2019 Sep; 26(5):320-330. PubMed ID: 31348046 [TBL] [Abstract][Full Text] [Related]
16. Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. Burnier L; Fernández JA; Griffin JH Blood Cells Mol Dis; 2013 Apr; 50(4):252-8. PubMed ID: 23385154 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel small molecule inhibitors of activated protein C. Sperandio O; Wildhagen KC; Schrijver R; Wielders S; Villoutreix BO; Nicolaes GA Thromb Res; 2014 Jun; 133(6):1105-14. PubMed ID: 24513148 [TBL] [Abstract][Full Text] [Related]
18. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Mosnier LO; Gale AJ; Yegneswaran S; Griffin JH Blood; 2004 Sep; 104(6):1740-4. PubMed ID: 15178575 [TBL] [Abstract][Full Text] [Related]